Adaptimmune Therapeutics Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
506
- Stock Symbol
-
ADAP
- Investments
-
1
- Share Price
-
$0.28
- (As of Friday Closing)
Adaptimmune Therapeutics General Information
Description
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Contact Information
Website
www.adaptimmune.comCorporate Office
- 60 Jubilee Avenue
- Milton Park
- Abingdon OX14 4RX
- England, United Kingdom
Corporate Office
- 60 Jubilee Avenue
- Milton Park
- Abingdon OX14 4RX
- England, United Kingdom
Adaptimmune Therapeutics Stock Performance
As of 23-May-2025, Adaptimmune Therapeutics’s stock price is $0.28. Its current market cap is $74.2M with 265M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.28 | $0.27 | $0.20 - $1.48 | $74.2M | 265M | 1.94M | -$0.25 |
Adaptimmune Therapeutics Financials Summary
As of 31-Mar-2025, Adaptimmune Therapeutics has a trailing 12-month revenue of $180M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (26,721) | 26,249 | 43,980 | 61,920 |
| Revenue | 179,639 | 178,032 | 60,281 | 27,148 |
| EBITDA | (56,341) | (59,261) | (108,659) | (158,426) |
| Net Income | (69,895) | (70,814) | (113,871) | (165,456) |
| Total Assets | 158,072 | 245,963 | 282,616 | 328,916 |
| Total Debt | 48,706 | 74,209 | 25,235 | 23,077 |
Adaptimmune Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adaptimmune Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Adaptimmune Therapeutics Comparisons
Industry
Financing
Details
Adaptimmune Therapeutics Competitors (53)
One of Adaptimmune Therapeutics’s 53 competitors is Poseida Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Transgene | Corporation | Illkirch-Graffenstaden, France | ||||
| Invectys | Venture Capital-Backed | Houston, TX | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA |
Adaptimmune Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adaptimmune Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adaptimmune Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Adaptimmune Therapeutics Acquisitions (1)
Adaptimmune Therapeutics’s most recent deal was a Merger/Acquisition with TCR2 Therapeutics for . The deal was made on 06-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TCR2 Therapeutics | 06-Mar-2023 | Merger/Acquisition | Pharmaceuticals |
Adaptimmune Therapeutics ESG
Risk Overview
Risk Rating
Updated March, 29, 2020
40.64 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 9,858
Rank
Percentile
Pharmaceuticals
Industry
of 709
Rank
Percentile
Biotechnology
Subindustry
of 346
Rank
Percentile
Adaptimmune Therapeutics FAQs
-
When was Adaptimmune Therapeutics founded?
Adaptimmune Therapeutics was founded in 2008.
-
Where is Adaptimmune Therapeutics headquartered?
Adaptimmune Therapeutics is headquartered in Abingdon, United Kingdom.
-
What is the size of Adaptimmune Therapeutics?
Adaptimmune Therapeutics has 506 total employees.
-
What industry is Adaptimmune Therapeutics in?
Adaptimmune Therapeutics’s primary industry is Pharmaceuticals.
-
Is Adaptimmune Therapeutics a private or public company?
Adaptimmune Therapeutics is a Public company.
-
What is Adaptimmune Therapeutics’s stock symbol?
The ticker symbol for Adaptimmune Therapeutics is ADAP.
-
What is the current stock price of Adaptimmune Therapeutics?
As of 23-May-2025 the stock price of Adaptimmune Therapeutics is $0.28.
-
What is the current market cap of Adaptimmune Therapeutics?
The current market capitalization of Adaptimmune Therapeutics is $74.2M.
-
What is Adaptimmune Therapeutics’s current revenue?
The trailing twelve month revenue for Adaptimmune Therapeutics is $180M.
-
Who are Adaptimmune Therapeutics’s competitors?
Poseida Therapeutics, Transgene, Invectys, Dicerna Pharmaceuticals, and Regulus Therapeutics are some of the 53 competitors of Adaptimmune Therapeutics.
-
What is Adaptimmune Therapeutics’s annual earnings per share (EPS)?
Adaptimmune Therapeutics’s EPS for 12 months was -$0.25.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
